Nishimura R, Shida K
Prostate Suppl. 1981;1:27-34. doi: 10.1002/pros.2990020506.
The goal of this study was to achieve clinical application of antiandrogens for the treatment of carcinoma of the prostate. Based on the results obtained from animal experiments and from a pilot clinical trial on prostatic cancer patients using various antiandrogenic compounds, chlormadinone acetate (CMA) was selected for a clinical trial in patients with carcinoma of the prostate. With nine universities and their affiliated hospitals participating, the therapeutic effect of CMA for carcinoma of the prostate was investigated nationwide. Highly satisfactory antitumor effects with CMA were observed in stage A and B patients of the primary treatment group. For stage C patients in the primary treatment group, good antitumor effects were obtained with CMA treatment. For stage D patients, however, results were poor. No serious side effects were observed in spite of the long period (as long as 6.3 years) and relatively large doses (100 mg daily) of CMA. Therefore, it was concluded that CMA can be recommended as a first choice drug for patients with carcinoma of the prostate.
本研究的目的是实现抗雄激素药物在前列腺癌治疗中的临床应用。基于动物实验结果以及对前列腺癌患者使用各种抗雄激素化合物的初步临床试验结果，选择醋酸氯地孕酮（CMA）用于前列腺癌患者的临床试验。由九所大学及其附属医院参与，在全国范围内研究了CMA对前列腺癌的治疗效果。在初始治疗组的A期和B期患者中观察到CMA具有高度令人满意的抗肿瘤效果。对于初始治疗组的C期患者，CMA治疗获得了良好的抗肿瘤效果。然而，对于D期患者，结果不佳。尽管CMA使用时间长（长达6.3年）且剂量相对较大（每日100毫克），但未观察到严重的副作用。因此，得出结论，CMA可推荐作为前列腺癌患者的首选药物。
